Loading organizations...
Aadi Bioscience is a commercial-stage biopharmaceutical company developing precision therapies for genetically defined cancers, based in Pacific Palisades, California. The organization focuses on treatments targeting mTOR pathway alterations, primarily through its FDA-approved lead product, FYARRO, designed for adult patients with advanced malignant perivascular epithelioid cell tumors. Prior to a major restructuring, the publicly traded enterprise operated with approximately 75 employees and generated $24.4 million in full-year product sales during 2023. In August 2024, the firm halted its Phase 2 clinical trials and reduced its research and development workforce by 80 percent to conserve capital. Under the leadership of executives including Dave Lennon and Brendan Delaney, the parent company rebranded as Whitehawk Therapeutics in March 2025 following a $100 million PIPE financing round, while divesting the FYARRO business and the Aadi name to Kaken Pharmaceuticals. Aadi Bioscience was founded in 2011 by Neil Desai.
Aadi Bioscience has raised $23.0M across 1 funding round.
Aadi Bioscience has raised $23.0M in total across 1 funding round.
Aadi Bioscience has raised $23.0M in total across 1 funding round.
Aadi Bioscience's investors include Jerry Xiao, Celgene, Decheng Capital, Helsinn, Star Summit Ventures, Mahendra Shah.
Aadi Bioscience has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in May 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 8, 2017 | $23M Series A | Jerry Xiao | Celgene, Decheng Capital, Helsinn, Star Summit Ventures, Mahendra Shah | Announced |
